Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study
Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intra...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1999 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of neuro-oncology - 1983, 41(1999) vom: März, Seite 255-259 |
| Übergeordnetes Werk: |
volume:41 ; year:1999 ; month:03 ; pages:255-259 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ198192401 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ198192401 | ||
| 003 | DE-627 | ||
| 005 | 20230505233837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1999 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ198192401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| 264 | 1 | |c 1999 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Aquino, Victor M. |4 oth | |
| 700 | 1 | |a Fort, Daniel W. |4 oth | |
| 700 | 1 | |a Kamen, Barton A. |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of neuro-oncology |d 1983 |g 41(1999) vom: März, Seite 255-259 |w (DE-627)NLEJ188986960 |w (DE-600)2007293-4 |x 1573-7373 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:1999 |g month:03 |g pages:255-259 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1023/A:1006149809479 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 1999 |c 3 |h 255-259 |g 5 | ||
| matchkey_str |
article:15737373:1999----::abpaifrhtetetfhlrniheldansdpici |
|---|---|
| hierarchy_sort_str |
1999 |
| publishDate |
1999 |
| allfields |
(DE-627)NLEJ198192401 DE-627 ger DE-627 rakwb eng Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. Springer Online Journal Archives 1860-2002 Aquino, Victor M. oth Fort, Daniel W. oth Kamen, Barton A. oth in Journal of neuro-oncology 1983 41(1999) vom: März, Seite 255-259 (DE-627)NLEJ188986960 (DE-600)2007293-4 1573-7373 nnns volume:41 year:1999 month:03 pages:255-259 extent:5 http://dx.doi.org/10.1023/A:1006149809479 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 41 1999 3 255-259 5 |
| spelling |
(DE-627)NLEJ198192401 DE-627 ger DE-627 rakwb eng Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. Springer Online Journal Archives 1860-2002 Aquino, Victor M. oth Fort, Daniel W. oth Kamen, Barton A. oth in Journal of neuro-oncology 1983 41(1999) vom: März, Seite 255-259 (DE-627)NLEJ188986960 (DE-600)2007293-4 1573-7373 nnns volume:41 year:1999 month:03 pages:255-259 extent:5 http://dx.doi.org/10.1023/A:1006149809479 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 41 1999 3 255-259 5 |
| allfields_unstemmed |
(DE-627)NLEJ198192401 DE-627 ger DE-627 rakwb eng Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. Springer Online Journal Archives 1860-2002 Aquino, Victor M. oth Fort, Daniel W. oth Kamen, Barton A. oth in Journal of neuro-oncology 1983 41(1999) vom: März, Seite 255-259 (DE-627)NLEJ188986960 (DE-600)2007293-4 1573-7373 nnns volume:41 year:1999 month:03 pages:255-259 extent:5 http://dx.doi.org/10.1023/A:1006149809479 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 41 1999 3 255-259 5 |
| allfieldsGer |
(DE-627)NLEJ198192401 DE-627 ger DE-627 rakwb eng Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. Springer Online Journal Archives 1860-2002 Aquino, Victor M. oth Fort, Daniel W. oth Kamen, Barton A. oth in Journal of neuro-oncology 1983 41(1999) vom: März, Seite 255-259 (DE-627)NLEJ188986960 (DE-600)2007293-4 1573-7373 nnns volume:41 year:1999 month:03 pages:255-259 extent:5 http://dx.doi.org/10.1023/A:1006149809479 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 41 1999 3 255-259 5 |
| allfieldsSound |
(DE-627)NLEJ198192401 DE-627 ger DE-627 rakwb eng Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study 1999 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. Springer Online Journal Archives 1860-2002 Aquino, Victor M. oth Fort, Daniel W. oth Kamen, Barton A. oth in Journal of neuro-oncology 1983 41(1999) vom: März, Seite 255-259 (DE-627)NLEJ188986960 (DE-600)2007293-4 1573-7373 nnns volume:41 year:1999 month:03 pages:255-259 extent:5 http://dx.doi.org/10.1023/A:1006149809479 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 41 1999 3 255-259 5 |
| language |
English |
| source |
in Journal of neuro-oncology 41(1999) vom: März, Seite 255-259 volume:41 year:1999 month:03 pages:255-259 extent:5 |
| sourceStr |
in Journal of neuro-oncology 41(1999) vom: März, Seite 255-259 volume:41 year:1999 month:03 pages:255-259 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of neuro-oncology |
| authorswithroles_txt_mv |
Aquino, Victor M. @@oth@@ Fort, Daniel W. @@oth@@ Kamen, Barton A. @@oth@@ |
| publishDateDaySort_date |
1999-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188986960 |
| id |
NLEJ198192401 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ198192401</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233837.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ198192401</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aquino, Victor M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fort, Daniel W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamen, Barton A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of neuro-oncology</subfield><subfield code="d">1983</subfield><subfield code="g">41(1999) vom: März, Seite 255-259</subfield><subfield code="w">(DE-627)NLEJ188986960</subfield><subfield code="w">(DE-600)2007293-4</subfield><subfield code="x">1573-7373</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:255-259</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1023/A:1006149809479</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">1999</subfield><subfield code="c">3</subfield><subfield code="h">255-259</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188986960 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1573-7373 |
| topic_title |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
v m a vm vma d w f dw dwf b a k ba bak |
| hierarchy_parent_title |
Journal of neuro-oncology |
| hierarchy_parent_id |
NLEJ188986960 |
| hierarchy_top_title |
Journal of neuro-oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188986960 (DE-600)2007293-4 |
| title |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| spellingShingle |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| ctrlnum |
(DE-627)NLEJ198192401 |
| title_full |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| journal |
Journal of neuro-oncology |
| journalStr |
Journal of neuro-oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1999 |
| contenttype_str_mv |
zzz |
| container_start_page |
255 |
| container_volume |
41 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase ii study |
| title_auth |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| abstract |
Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. |
| abstractGer |
Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. |
| abstract_unstemmed |
Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study |
| url |
http://dx.doi.org/10.1023/A:1006149809479 |
| remote_bool |
true |
| author2 |
Aquino, Victor M. Fort, Daniel W. Kamen, Barton A. |
| author2Str |
Aquino, Victor M. Fort, Daniel W. Kamen, Barton A. |
| ppnlink |
NLEJ188986960 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| up_date |
2024-07-06T10:43:52.999Z |
| _version_ |
1803826110659559424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ198192401</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233837.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ198192401</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83±11%. The median duration of follow-up was 38.6 months (range 18–63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aquino, Victor M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fort, Daniel W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamen, Barton A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of neuro-oncology</subfield><subfield code="d">1983</subfield><subfield code="g">41(1999) vom: März, Seite 255-259</subfield><subfield code="w">(DE-627)NLEJ188986960</subfield><subfield code="w">(DE-600)2007293-4</subfield><subfield code="x">1573-7373</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:1999</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:255-259</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1023/A:1006149809479</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">1999</subfield><subfield code="c">3</subfield><subfield code="h">255-259</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3995275 |